中国大陆抗击乙型肝炎病毒感染的进展和挑战

王岩; 贾继东

中国大陆抗击乙型肝炎病毒感染的进展和挑战

王岩,
贾继东

首都医科大学北京友谊医院肝病中心

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2224
- HTML全文浏览量: 3
- PDF下载量: 742
- 被引次数: 0
出版历程
- 出版日期: 2010-04-20

The progress and challenge of combating HBV infection in Chinese mainland

摘要

- 肝炎,乙型,慢性 /
- 中国
- hepatitis B /
- chronic

HTML全文

参考文献(23)

[1]Zeng G, Wang G, Wen G, et al.Geographic distribution, virologicand clinical characteristics of hepatitis B virus genotypes inChina[J].J Viral Hepatitis, 2005, 12 (6) ∶609-617.

[2]Liang XF, Bi SL, Yang WZ, et al.Evaluation of the Impact of Hep-atitis B Vaccination among Children Born during 1992-2005 inChina[J].J Infect Dis, 2009, 200 (1) ∶39-47.

[3]Liang XF, Bi SL, Yang W, et al.Epidemiological serosurvey of hepa-titis B in China-declining HBV prevalence due to hepatitis B vac-cination[J].Vaccine, 2009, 27 (47) ∶6550-6557.

[4]崔富强, 卢永, 王富珍, 等.中国2006年乙型肝炎报告病例构成分析[J].中国流行病学, 2007, 28 (9) ∶872-874.

[5]Wang FS.Clinical immune characterization of hepatitis B virus in-fection and implications for immune intervention:Progress and chal-lenges[J].Hepatol Res, 2007, 37 (3) ∶339-346.

[6]Zhang Z, Zhang JY, Wherry E, et al.Dynamic programmed death1 expression by virus-specific CD8 Tcells correlates with the out-come of acute hepatitis B[J].Gastroenteology, 2008, 134 (7) ∶1938-1949.

[7]Chen L, Zhang W, Wang FS, et al.B7-H1 up-regulation on mye-loid dendritic cells significantly suppresses T cell immune functionin patients with chronic hepatitis B[J].J Immunol, 2007, 178 (10) ∶6634-6641.

[8]Xu DP, Fu JL, Jin L, et al.Circulating and liver resident CD4-CD25-regulatory Tcells actively influence the antiviral immune re-sponse and disease progression in patients with hepatitis B[J].J Im-munol, 2006, 177 (1) ∶739-747.

[9]Fu JL, Xu DP, Liu ZW, et al.Increased Regulatory TCells CorrelateWith CD8 T-Cell Impairmentand Poor Survival in Hepatocellular Car-cinoma Patients[J].Gastroenteology, 2007, 132 (7) ∶2328-2339.

[10]Zhang YJ, Zhang Z, Lin F, et al.Interleukin-17-producing CD4Tcells increase with severity of liver damage in patients with chronichepatitis B[J].Hepatology, 2010, 51 (1) ∶81-91.

[11]Chen L, Zhang Q, Yu DM, et al.Early changes of hepatitis B virusquasispecies during lamivudine treatment and the correlation withantiviral efficacy[J].J Hepatol, 2009, 50 (5) ∶895-905.

[12]Wu XN, You H, Bai QX, et al.HBVpromotes collagen typeⅠex-pression through P38MAPK pathway in human hepatic stellate cellline, LX2 cell[J].Hepatol Int, 2010, 4∶12.

[13]Li DL, Zheng LH, Lei J, et al.CD24 polymorphisms affect risk andprogression of chronic hepatitis B virus infection[J].Hepatology, 2009, 50 (3) ∶735-742.

[14]Liaw YF, Joseph J, Sung, et al.Lamivudine for patients with chro-nic hepatitis B and advanced liver disease[J].N Engl J Med, 2004, 351 (15) ∶1521-1531.

[15]Zeng MD, Mao YM, Yao GB, et al.A double-blind randomizedtrial of adefovir dipivoxil in chinese subjects with HBeAg-positivechronic hepatitis B[J].Hepatology, 2006, 44 (1) ∶108-116.

[16]Yao GB, Chen CW, Lu WL, et al.Virologic, serologic, and bio-chemical outcomes through 2 years of treatment with entecavir andlamivudine in nucleoside-na ve Chinese patients with chronic hep-atitis B:a randomized, multicenter study[J].Hepa Interal, 2008, 2 (4) :486-493.

[17]Lai CH, Edward Gane, LiawYF, et al.Telbivudine versus lamivu-dine in patients with chronic hepatitis B[J].N Engl J Med, 2007, 357 (25) ∶2576-2588.

[18]Hou JL, Yin YK, Xu DZ, et al.Telbivudine versus lamivudine in chi-nese patients with chronic hepatitis B:results at1 year of a randomized, double-blind trial[J].Hepatology, 2008, 47 (4) ∶447-454.

[19]Liaw YF, Edward Gane, Nancy L, et al.2-Year GLOBE trial Re-sults:Telbivudine is superior to lamivudine in patients with chronichepatitis B[J].Gastroentorology, 2009, 136 (2) ∶486-495.

[20]Lau GKK, Piratvisuth T, Luo KX, et al.Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hep-atitis B[J].N Engl J Med, 2005, 352 (26) ∶2682-2695.

[21]Patrick M, Lau GKK, Ferruccio B, et al.Peginterferon alfa-2a a-lone, lamivudine alone, and the two in combination in patients withHBeAg-negative chronic hepatitis B[J].N Engl J Med, 2004, 351 (12) ∶1206-1217.

[22]Zhao H, Fuat K, Wan MB, et al.Genotype B and younger patientage associated with better response to low-dose therapy:A trialwith pegylated/nonpegylated interferon-α-2b for Hepatitis B eAntigen-positive patients with chronic hepatitis B in China[J].Clinical Infectious Diseases, 2007, 44 (4) ∶541-548.

[23]Chinese Society of Hepatology, Chinese Medical Association;Chi-nese Society of Infectious Diseases, Chinese Medical Association.Guideline on prevention and treatment of chronic hepatitis B in Chi-na (2005) [J].Chin Med J, 2007, 120 (24) ∶2159-2173.

施引文献

资源附件(0)

访问统计